Problematic patent settlements continue to fall in number, says European Commission
This article was originally published in SRA
Originator and generic manufacturers are entering into fewer "potentially problematic" settlements that violate antitrust regulations and delay market entry of generic medicines, a new monitoring exercise by the European Commission has revealed1.
You may also be interested in...
England’s health technology appraisal body, NICE, and the UK medicines regulator, the MHRA, are working together to align their process timelines so that access to medicines is “maintained and enhanced.”
Industry access to real world data for regulatory and market access purposes in Asia Pacific compares poorly with the US.
Draft guidelines due out for consultation this week in Italy are expected to shed more light on what companies will have to reveal during pricing and reimbursement negotiations.